Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Selective Brain Penetrant CDK4 Inhibitor
- Development stage
- Preclinical
- Lead developer
- Eilean Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Selective Brain Penetrant CDK4 Inhibitor is a small molecule inhibitor being developed by Eilean Therapeutics Australia for the treatment of solid tumors. Unlike first-generation CDK4/6 inhibitors which target both CDK4 and CDK6, this agent is designed to be highly selective for CDK4. This selectivity is intended to reduce hematological toxicities, such as neutropenia, which are primarily associated with CDK6 inhibition, potentially allowing for continuous dosing and improved therapeutic outcomes. Furthermore, the molecule is specifically engineered for high brain penetrance, making it a potential candidate for treating primary central nervous system (CNS) tumors or brain metastases from other solid tumors. It is currently in the early stages of development.
- Other names
- CDK4 inhibitor (Eilean Therapeutics)Eilean CDK4 inhibitor
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on Selective Brain Penetrant CDK4 Inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selective Brain Penetrant CDK4 Inhibitor.